 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2020, vol. 26, issue2
Subject Area: Medicine
-
DOI: 10.5272/jimab.2020262.3102
Published online: 29 April 2020
Case report
J of IMAB. 2020 Apr-Jun;26(2):3102-3106
SMO (SMOOTHENED TRANSMEMBRANE PROTEIN) INHIBITORS (VISMODEGIB) IN TREATMENT OF BASAL CELL CARCINOMA (BCC) OF OCULAR ADNEXA
Georgi Balchev
, Chavdar Balabanov, Snezhana Murgova,
Ophthalmology Clinic, Medical University Pleven, Bulgaria.
ABSTRACT:
Basal Cell Carcinoma (BCC) is one of the well spread malignant skin cancers. Eighty percent of it occurs in the head-neck area of which 20% in the eyelids. The major genes for BCC are: PTCH1 and PTCH2. PTCH1 supresses transmembrane Smoothened (SMO) protein, while PTCH2 have his role uncleared, but there are evidences for involvement in Hedgehog signalling pathway. From all cases of BCC of adnexa, advanced BCC represents a small percentage of 1-10%. Advanced BCC has his two forms of metastatic mBCC and local advanced laBCC. The surgical approach is a mainstay in the treatment of BCC. Some cases the anatomical and functional results are expected to be poor, due to difficult location of the tumour, such patients with laBCC and mBCC can benefit from medical treatment together with surgery and radiotherapy or alone. Systemic treatment, as of Vismodegib is a good candidate for these patients with mild to moderate side effect’s profile.
Keywords: basal cell carcinoma, Eyelid, Oncology, Vismodegib, Ophthalmology, free cutaneous graft,
- Download FULL TEXT /PDF 1383 KB/
Please cite this article as: Balchev G, Balabanov C, Murgova S. SMO (Smoothened transmembrane protein) inhibitors (Vismodegib) in treatment of Basal Cell Carcinoma (BCC) of ocular adnexa. J of IMAB. 2020 Apr-Jun;26(2):3102-3106. DOI: 10.5272/jimab.2020262.3102
Correspondence to: Georgi Balchev, Medical University Pleven; 91, Vladimir Vazov str., 2-nd Clinical Base. Pleven, Bulgaria; E-mail: georgi@balchev.org
REFERENCES:
1. Saleh GM, Desai P, O’Collin JR, Ives A, Jones T, Hussain B, Incidence of eyelid basal cell carcinoma in England: 2000-2010. Br J Ophthalmol. 2017 Feb;101(2):209-212. [PubMed]
2. Furdova A, Horkovicova K, Babal P, Kobzova D, Ondrusova M. [Non-melanotic Tumors of the Eyelids Skin and Inner Corner - Basocellular Carcinoma.] [in Czech]. Cesk Slov Oftalmol. 2015 Winter;71(6):293-301. [PubMed]
3. Balabanov Ch. [Tumors of the eye and adnexa.] Medical University Pleven. 2019. pp.130-131. [in Bulgarian].
4. Zlatarova Z. [Surgery of the eyelids.] Medical University Varna. 2018. pp.156-264. [in Bulgarian].
5. Basal cell skin cancer. NCCN. [Internet]
6. Reis A, Küster W, Linss G, Gebel E, Hamm H, Fuhrmann W, et al. Localisation of gene for the naevoid basal-cell carcinoma syndrome. Lancet. 1992 Mar 7;339(8793):617. [PubMed] [Crossref]
7. Tabata T, Kornberg TB. Hedgehog Is a Signaling Protein With a Key Role in Patterning Drosophila Imaginal Discs. Cell. 1994 Jan 14;76(1):89-102. [PubMed]
8. Stacey SN, Helgason H, Gudjonsson SA, Thorleifsson G, Zink F, Sigurdsson A, et al. New basal cell carcinoma susceptibility loci. Nat Commun. 2015 Apr 9;6:6825. [PubMed] [Crossref]
9. Deraemaecker R. Les carcinomescutanés. In: Thérapeutique du cancer. Morere JF, Mornex F, Soulieres D. Springer, Paris. 2011. p 685-708. [in French] [Crossref]
10. Roewert HJ, Lange-Asschenfeldt B. Stockfleth E, Kerl H. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007 Dec;157(Suppl 2):47-51. [PubMed]
11. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. BMJ.2003 Oct 4;327(7418):794-8. [PubMed]
12. Scrivener Y, Grosshans E, Cribier B, Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. British J Dermatology. 2002 Jul;147(1):41-7. [PubMed]
13. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features,diagnosis, histopathology, and management. Yale J Biol Med. 2015 Jun 1;88(2):167-79. [PubMed]
14. Basal Cell Carcinoma Risk Factors. Skin Cancer Foundation. May 2019. [Internet]
15. Ting PT, Kasper R, Arlette JP. Metastatic Basal Cell Carcinoma: Report of Two Cases and Literature Review. J Cutan Med Surg. 2005 Jan;9(1):10–15. [PubMed] [Crossref]
16. Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: Report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9. [PubMed] [Crossref]
17. von Domarus H, Stevens PJ. Metastatic Basal Cell Carcinoma. Report of Five Cases and Review of 170 Cases in the Literature. J Am Acad Dermatol. 1984 Jun;10 (6), 1043-60. [PubMed] [Crossref]
18. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive Basal Cell Carcinoma: Presentation, Pathogenesis, and Management. Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402. [PubMed] [Crossref]
19. Jackson R, Adams RH. Horrifying Basal Cell Carcinoma: A Study of 33 Cases and a Comparison With 435 Non-Horror Cases and a Report on Four Metastatic Cases. J Surg Oncol. 1973 May;5(5):431-63. [PubMed] [Crossref]
20. Blewitt RW. Why Does Basal Cell Carcinoma Metastasize So Rarely? Int J Dermatol. 1980 Apr;19(3):144-6. [PubMed]
21. Randle H, Basal cell carcinoma: Identification and treatment of the high-risk patient. Dermatol Surg. 1996 Mar;22(3):255-61. [PubMed]
22. Batra RS, Kelly LC, Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol. 2002 Aug;138(8):1043-51. [PubMed]
23. Ratner D, Lowe L, Johnson TM, Fader DJ., Perineural spread of basal cell carcinomas treated with Mohs micrographic surgery. Cancer. 2000 Apr 1;88(7):1605-13. [PubMed]
24. Niazi ZB LB, Perineural infiltration in basal cell carcinomas. Br J Plast Surg. Mar 1993 Mar;46(2):156-7. [PubMed]
25. Griffiths R, Audit of histologically incompletely excised basal cell carcinomas: Recommendations for management by re-excision. Br J Plast Surg. 1999 Jan;52(1):24-8. [PubMed]
26. Robinson J, Fisher SG, Recurrent basal cell carcinoma after incomplete resection. Arch Dermatol. 2000 Nov;136(11):1318-24. [PubMed]
27. Richmond J, Devie RM, The significance of incomplete excision in patients with basal cell carcinoma. Br J Plast Surg. 1987 Jan;40(1):63-7. [PubMed]
28.Allali J, D’Hermies F, Renard G., Basal cell carcinomas of the eyelids. Ophthalmologica. 2005; 219(2):57-71. [PubMed]
29. Sexton M, Jones DB, Maloney ME, Histologic pattern analysis of basal cell carcinoma, Journal of American Academy of Dermatology, 1990; 23:1118-26 [PubMed]
30. Siegle R, Macmillan J, Pollack SV. Infiltrative basal cell carcinoma: A nonsclerosing subtype. J Dermatol Surg Oncol. 1986 Aug;12(8):830-6. [PubMed]
31. Tromovitch T, Stegman SJ. Microscopic-controled excision of cutaneous tumors. Cancer. 1978; 41(2):653-8. [PubMed]
32. Jacobs G, Rippley JJ, Altini M, Prediction of aggressive behavior in basal cell carcinoma. Cancer. 1982; 49: 533-7 [PubMed]
33. Schuller D, Berg JW, Sherman G, Krause CJ. Cutaneous basosquamous carcinoma of the head and neck: a comparative analysis. Otolaryngol Head Neck Surg (1979). 1979 Jul-Aug;87(4):420-7. [PubMed]
34. Shi Y, Jia R, Fan X. Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment. Onco Targets Ther. 2017 May 8;10:2483-9 [PubMed] [Crossref]
35. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD,et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 May 16;17(1):332 [PubMed] [Crossref]
36. Vismodegib. US Food and Drug Administration. 2012. [Internet]
37.Koekelkoren FHJ, Roodbergen SL, Baerveldt EM, Maat APWM, Monserez DA, Grunhagen DJ, et al. Vismodegib for Giant, Locally Advanced, Basal Cell Carcinoma and Its Complex Position in Clinical Practice. JAAD Case Rep. 2019 Mar;5(3):267-270. [PubMed] [Crossref].
Received: 22 November 2019
Published online: 29 April 2020